Literature DB >> 3590284

Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion.

E A Schmalzer, J O Lee, A K Brown, S Usami, S Chien.   

Abstract

Viscosity (eta) in a blood suspension is affected by the total hematocrit (HT) as well as by the deformability of the cells. The impact of these combined factors on the rheologic behavior of sickle cell suspensions and on guidelines for transfusion has not been explored fully. Therefore, the eta of mixtures of washed normal (AA) and sickle (SS) red cells was determined in a rotational viscosimeter as a function of the hematocrit level of SS cells (HS), HT, oxygen tension (PO2), and shear rate. The ratio HT:eta can be taken as an index of potential oxygen delivery. The optimal HT (for maximum HT:eta) became progressively higher as the HS or the HS:HT ratio was lowered: at a given HT, HT:eta rose with a decrease in HS, especially at low HS values. These data support the concept that simple transfusion alone is not as beneficial to the patient as exchange transfusion and that substantial benefit can be obtained by bringing the patient to very low HS levels. The finding that eta rose with HT more steeply when the HS:HT ratio rather than HS was held constant suggested that the absolute level of HS may be more useful than the HS:HT ratio as a guide for a transfusion regimen.

Entities:  

Mesh:

Year:  1987        PMID: 3590284     DOI: 10.1046/j.1537-2995.1987.27387235626.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  26 in total

Review 1.  Managing sickle cell disease.

Authors:  Susan Claster; Elliott P Vichinsky
Journal:  BMJ       Date:  2003-11-15

2.  Exchange transfusion therapy and its effects on real-time microcirculation in pediatric sickle cell anemia patients: an intravital microscopy study.

Authors:  Anthony T W Cheung; Joshua W Miller; Maricel G Miguelino; Wilson J To; Jiajing Li; Xin Lin; Peter C Chen; Sandra L Samarron; Ted Wun; Theodore Zwerdling; Ralph Green
Journal:  J Pediatr Hematol Oncol       Date:  2012-04       Impact factor: 1.289

3.  Recommendations for the transfusion of red blood cells.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

Review 4.  Pulmonary vascular resistance and viscosity: the forgotten factor.

Authors:  Julien I E Hoffman
Journal:  Pediatr Cardiol       Date:  2011-03-25       Impact factor: 1.655

Review 5.  Sickle cell states and the anaesthetist.

Authors:  D W Esseltine; M R Baxter; J C Bevan
Journal:  Can J Anaesth       Date:  1988-07       Impact factor: 5.063

6.  Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.

Authors:  Patricia M Fortin; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2018-08-01

Review 7.  Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Ian R Hambleton; Gavin Cho
Journal:  Cochrane Database Syst Rev       Date:  2016-05-20

8.  Sickle cell disease: selected aspects of pathophysiology.

Authors:  T Alexy; S Sangkatumvong; P Connes; E Pais; J Tripette; J C Barthelemy; T C Fisher; H J Meiselman; M C Khoo; T D Coates
Journal:  Clin Hemorheol Microcirc       Date:  2010       Impact factor: 2.375

9.  Stroke in Children with Sickle Cell Disease.

Authors:  Fenella J. Kirkham; Michael R. DeBaun
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

10.  Low-shear red blood cell oxygen transport effectiveness is adversely affected by transfusion and further worsened by deoxygenation in sickle cell disease patients on chronic transfusion therapy.

Authors:  Jon Detterich; Tamas Alexy; Miklos Rabai; Rosalinda Wenby; Ani Dongelyan; Thomas Coates; John Wood; Herbert Meiselman
Journal:  Transfusion       Date:  2012-08-06       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.